RT Journal Article
T1 The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach
A1 Ríos-Tamayo, Rafael
A1 Puig, Noemí
A1 Algarín, Macarena
A1 García de Veas Silva, José Luís
A1 Barbosa, Nuno
A1 Encinas, Cristina
A1 Hernández, José Ángel
A1 Alonso, Rafael
A1 Campos, María Luisa
A1 Rodríguez, Teresa
A1 Leivas, Alberto
A1 Olivares, María José
A1 Sanchez-Perez, Maria-Jose
A1 Paiva, Bruno
A1 Lahuerta, Juan José
A1 Martínez-López, Joaquín
K1 Multiple myeloma
K1 Heavy/light chain assay
K1 Hevylite
K1 Diagnosis
K1 Prognosis
K1 Monitoring
K1 Mieloma múltiple
K1 Cadenas pesadas de inmunoglobulina
K1 Cadenas ligeras de inmunoglobulina
K1 Inmunoensayo
K1 Procesamiento automatizado de datos
K1 Diagnóstico
K1 Pronóstico
K1 Monitorización del ambiente
AB Despite tremendous progress being made in recent years, multiple myeloma (MM) remains a challenging disease. The laboratory plays a critical role in the overall management of patients. The diagnosis, prognosis, clinical monitoring and evaluation of the response are key moments in the clinical care process. Conventional laboratory methods have been and continue to be the basis of laboratory testing in monoclonal gammopathies, along with the serum free light chain test. However, more accurate methods are needed to achieve new and more stringent clinical goals. The heavy/light chain assay is a relatively new test which can overcome some of the limitations of the conventional methods for the evaluation of intact immunoglobulin MM patients. Here, we report an update of the evidence accumulated in recent years on this method regarding its use in MM.
PB MDPI
YR 2021
FD 2021-10-30
LK http://hdl.handle.net/10668/4422
UL http://hdl.handle.net/10668/4422
LA en
NO Ríos-Tamayo R, Puig N, Algarín M, García de Veas Silva JL, Barbosa N, Encinas C, et al. The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach. Diagnostics. 2021 Oct 30;11(11):2020
DS RISalud
RD Apr 5, 2025